Lipella Pharmaceuticals to Present Abstract at 2024 ASCO Annual Meeting

PITTSBURGH, May 29, 2024 – Lipella Pharmaceuticals (Nasdaq: LIPO), a biotechnology firm in the clinical stage of addressing severe diseases with unmet medical needs, has announced the publication of new preclinical findings at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This event is scheduled from May 31 to June 4 in Chicago, IL, and online. Lipella's abstract titled "Intravesical Administration of Pembrolizumab for Bladder Tumor- A Potential Strategy to Minimize Drug Toxicity" showcases promising preclinical data from the use of LP-50 (intravesical pembrolizumab) in induced murine non-muscle invasive bladder cancer (NMIBC).

Highlighting the preclinical results, Dr. Michael Chancellor, Lipella Pharmaceuticals' Chief Medical Officer, stated, “LP-50 is formulated for intravesical administration aimed at treating non-muscle invasive bladder cancer. Our studies indicate that LP-50 not only enhances efficacy but also reduces systemic toxicity.”

The American Cancer Society predicts that approximately 83,190 new cases of bladder cancer will be diagnosed in the United States in 2024. This underscores the urgent need for effective treatments for bladder cancer, particularly non-muscle invasive types.

About LP-50

LP-50 is an intravesical formulation that includes immunoglobulins and local, intravesical PD-1 inhibition, targeting non-muscle invasive bladder cancer. The preclinical program suggests that LP-50 can enhance therapeutic efficacy while minimizing systemic side effects. Detailed information about this research is available in the International Journal of Molecular Sciences, 2024 edition, and a US patent publication that discusses the intravesical delivery of hydrophilic therapeutic agents using liposomes.

About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals is a biotechnology company in the clinical stage, specializing in the development of new drugs by reformulating active agents found in generic medications. The company focuses on optimizing these reformulations for new applications, targeting diseases with significant morbidity and mortality that currently lack effective treatments. Lipella went public in December 2022.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!